196 related articles for article (PubMed ID: 36029752)
1. Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review.
Nabizadeh F; Ramezannezhad E; Kazemzadeh K; Khalili E; Ghaffary EM; Mirmosayyeb O
J Clin Neurosci; 2022 Oct; 104():118-125. PubMed ID: 36029752
[TBL] [Abstract][Full Text] [Related]
2. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D
Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085
[TBL] [Abstract][Full Text] [Related]
3. Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review.
Nabizadeh F; Noori M; Rahmani S; Hosseini H
J Clin Neurosci; 2023 May; 111():57-70. PubMed ID: 36963124
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Achiron A; Dolev M; Menascu S; Zohar DN; Dreyer-Alster S; Miron S; Shirbint E; Magalashvili D; Flechter S; Givon U; Guber D; Stern Y; Polliack M; Falb R; Gurevich M
Mult Scler; 2021 May; 27(6):864-870. PubMed ID: 33856242
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
Dreyer-Alster S; Menascu S; Mandel M; Shirbint E; Magalashvili D; Dolev M; Flechter S; Givon U; Guber D; Stern Y; Miron S; Polliack M; Falb R; Sonis P; Gurevich M; Achiron A
J Neurol Sci; 2022 Mar; 434():120155. PubMed ID: 35091386
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
[TBL] [Abstract][Full Text] [Related]
7. Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity.
Kavosh A; Ashtari F; Naghavi S; Adibi I; Shaygannejad V; Karimi Z; Arabi S; Rahimi M; Mazaheri S
Mult Scler Relat Disord; 2022 May; 61():103708. PubMed ID: 35349883
[TBL] [Abstract][Full Text] [Related]
8. Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.
Pernicová E; Macounová P; Krsek M; Maďar R
Eur Neurol; 2023; 86(4):263-276. PubMed ID: 36871554
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark.
Stastna D; Elberling F; Pontieri L; Framke E; Horakova D; Drahota J; Nytrova P; Magyari M
Eur J Neurol; 2024 Mar; 31(3):e16163. PubMed ID: 38015454
[TBL] [Abstract][Full Text] [Related]
10. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
[TBL] [Abstract][Full Text] [Related]
11. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis.
Etemadifar M; Abhari AP; Nouri H; Sigari AA; Piran Daliyeh SM; Maracy MR; Salari M; Maleki S; Sedaghat N
Hum Vaccin Immunother; 2022 Dec; 18(1):2041945. PubMed ID: 35201963
[TBL] [Abstract][Full Text] [Related]
12. Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.
Shabani M; Shobeiri P; Nouri S; Moradi Z; Amenu RA; Mehrabi Nejad MM; Rezaei N
Eur J Med Res; 2024 Jan; 29(1):55. PubMed ID: 38229141
[TBL] [Abstract][Full Text] [Related]
13. A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination.
Canney M; Atiquzzaman M; Cunningham AM; Zheng Y; Er L; Hawken S; Zhao Y; Barbour SJ
J Am Soc Nephrol; 2022 Dec; 33(12):2247-2257. PubMed ID: 36332971
[TBL] [Abstract][Full Text] [Related]
14. Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
Witman Tsur S; Adrian Zaher E; Tsur M; Kania K; Kalinowska-Łyszczarz A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917860
[TBL] [Abstract][Full Text] [Related]
15. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
16. Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
Bruno A; Buttari F; Dolcetti E; Azzolini F; Borrelli A; Lauritano G; Di Caprio V; Rizzo FR; Gilio L; Galifi G; Furlan R; Finardi A; Guadalupi L; Musella A; Mandolesi G; Centonze D; Stampanoni Bassi M
Mult Scler; 2023 Oct; 29(11-12):1383-1392. PubMed ID: 37698019
[TBL] [Abstract][Full Text] [Related]
17. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
Etemadifar M; Sigari AA; Sedaghat N; Salari M; Nouri H
Hum Vaccin Immunother; 2021 Oct; 17(10):3481-3483. PubMed ID: 34015240
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis.
Seyedmirzaei H; Salabat D; KamaliZonouzi S; Teixeira AL; Rezaei N
Mult Scler Relat Disord; 2024 Mar; 83():105472. PubMed ID: 38316078
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports.
Alsudais AS; Alkanani RS; Fathi AB; Almuntashiri SS; Jamjoom JN; Alzhrani MA; Althubaiti A; Radi S
BMC Endocr Disord; 2023 Aug; 23(1):164. PubMed ID: 37542216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
